Health Business Blog

Health care business consultant and policy expert David E. Williams share his views

Interview with Lean TaaS CEO Mohan Giridharadas

Mohan photo
Lean TaaS CEO Mohan Giridharadas

Mohan Giridharadas earned an MBA from Stanford and was a senior director for years at McKinsey, but it took an insight from a casual conversation at a Silicon Valley cocktail party to give him the direction for Lean TaaS, where he’s founder and CEO. A decade and $200 M of investment later, the company is leading the way in operational optimization of healthcare assets.

In healthcare, big organizations often use pencil and paper and Excel spreadsheets for tasks like scheduling infusion centers. And the results are predictably dismal. Lean TaaS applies the more sophisticated optimization approaches used by companies like UPS and Delta Airlines to bring healthcare into the modern era.

Mohan shares his story in this episode of the HealthBiz podcast.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with Seqster CEO Ardy Arianpour

Ardy Arianpour
Ardy Arianpour, Seqster CEO

Ardy Arianpour arrived in San Diego as a six year old immigrant from the Middle East and didn’t waste time getting going. By 16 he was working at the Salk Institute and after college pursued a series of sales and marketing roles, even finding time to get involved in a landmark gene patent lawsuit at the US Supreme Court.

As co-founder and CEO of Seqster, he’s bringing person-centric interoperability to the masses. Seqster has the wind at its back. And with the 21st Century Cures Act, Ardy contends that Seqster essentially is the law.

In this episode of the HealthBiz podcast, Ardy explains what it means to be a data artist, how to be patient centric when your customers are not the patients, and why Seqster is different from everything else out there. He also digs in to the reasons behind Takeda’s investment in the company and the recent partnerships with Medable and Datavant.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with Glympse Bio CEO Caroline Loew

Caroline Loew Picture
Glympse Bio CEO Caroline Loew

Glympse Bio CEO Caroline Loew grew up in England with the expectation that she could do anything. After all, her grandmother managed a hotel when she was in her 20s and her parents always supported her ambitions. And while for most students, organic chemistry is a weed out class for pre-med Caroline actually fell in love with the subject and pursued her PhD.

She then made her career in drug development at big pharma where she built a strong and broad foundation across multiple domains that prepared her to run a biotech company.

In this episode of the HealthBiz podcast Caroline shares her personal and career background and what it’s like to lead a high-profile spinout from MIT with prominent board members and investors. We also talk about sexism in science and business and I ask her to explain why she appears in so many podcasts.

Like  a few of my other guests, one of her book recommendations is the Hard Thing About Hard Things by Ben Horowitz. She’s also a fan of General Stan McChrystal’s book Team of Teams. Recent recommended reads include Editing Humanity by Kevin Davies  and No Rules Rules by Reed Hastings and Erin Meyer.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with CytImmune CEO Saba Malak

Saba Malak photo
CytImmune CEO Saba Malak

I first encountered Saba Malak when I was a summer consultant at Boston Consulting Group and he was a new MBA. We stayed in touch and when I became chairman of Advanced Practice Strategies a few years later, Saba joined the board as lead investor.

Since then, Saba has invested in various healthcare and biotech companies in the public and private markets. I never thought of Saba as an operating executive –and apparently neither did he– but a couple of years ago he became so enamored with a company he’d invested in that he decided to take the plunge and become CEO.

That company, CytImmune is establishing a global leadership role in the field of cancer nanomedicine. It is a platform company with products of its own in development. The potential is huge, and in this episode of the HealthBiz podcast Saba explains the technology and why he is confident it will ultimately help patients. The company has a Phase II development collaboration with the National Cancer Institute, and is scaling up its manufacturing to be ready.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with Curation Health CEO Kevin Coloton

KevinColoton1
Curation Health CEO Kevin Coloton

Kevin Coloton always knew he’d be in healthcare. After all, both of his parents and all of their friends worked in the field. And as a high school athlete he frequently found himself injured and under the care of a physical therapist.

Kevin started off in PT and then gravitated to the business side of healthcare, earning an MBA and accumulating experience as a consultant, hospital administrator, and start-up executive. Just over three years ago he founded Curation Health to simplify care delivery under risk-based contracts. Curation preaches three keys to ensure success: A pre-visit review, contextual recommendations that make it easy for a physician to act, and a post-visit review by a medical coder.

After medical visits dried up in early 2020, fee for service providers looked on with envy at their value based peers who continued to get paid as usual. Curation Health can help, but Kevin explains that FFS providers typically under-appreciate the hard right turn that’s needed to succeed in value based care when your infrastructure is built on a fee for service chassis.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.